TG-1701

· TG Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TG-1701, covering 2024-07-19 to 2024-07-19. Get the full timeline:

Most recent: Clinical Trial Update: Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies [Phase 1]

See pricing